Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 370-375

  Kojima, Toshihisa ^a   Kaneko, Atsushi ^b   Hirano, Yuji ^c   Ishikawa, Hisato ^d   Miyake, Hiroyuki ^e   Takagi, Hideki ^f   Yabe, Yuichiro ^g   Kato, Takefumi ^h   Terabe, Kenya ⁱ   Fukaya, Naoki ^j   Tsuchiya, Hiroki ^f   Shioura, Tomone ^k   Funahashi, Koji ^a   Hayashi, Masatoshi ^a   Kato, Daizo ^a   Matsubara, Hiroyuki ^a   Ishiguro, Naoki ^a,l  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d NAGANO RED CROSS HOSPITAL   (Japan)

^e Ichinomiya Municipal Hospital   (Japan)

^f Nagoya Kyoritsu Hospital   (Japan)

^g TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^h Kato Orthopedic Clinic   (Japan)

ⁱ Fukuroi Municipal Hospital   (Japan)

^j Kariya Toyota General Hospital   (Japan)

^k Shizuoka Kosei Hospital   (Japan)

^l NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Interleukin 6; Patient reported outcome; Remission; Rheumatoid arthritis; Tocilizumab

Indexed keywords

METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; ARTICLE; BOOLEAN APPROACH; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; REGISTRIES; REMISSION INDUCTION; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865369156     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0528-2     Document Type: Article

References (19)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90. (Pubitemid 41612204)
3. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. (Pubitemid 43122183)
4. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375-82.
5. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Where the rubber meets the road. Arthritis Rheum. 2008;59:757-9. (Pubitemid 351847557)
6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
7. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86.
8. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7. (Pubitemid 47309731)
9. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin- 6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebocontrolled, randomised trial. Lancet. 2008;371:987-97. (Pubitemid 351392039)
10. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
11. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
12. Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2011;21:122-33.
13. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1-10. (Pubitemid 19187402)
14. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010;69:1058-64.
15. Kojima M, Kojima T, Ishiguro N, et al. Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res. 2009;67:425-31.
16. Kojima M, Kojima T, Suzuki S, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:1018-24.
17. Pace MC, Mazzariello L, Passavanti MB, et al. Neurobiology of pain. J Cell Physiol. 2006;209:8-12. (Pubitemid 44318663)
18. Merskey HB, editor. Classification of chronic pain syndromes and definitions of pain terms. Seatle: IASP Press; 1994.
19. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: A micro-simulation economic decision model. Curr Med Res Opin. 2011;27:713-30.